WRB Stock Analysis: W. R. Berkley | NYSE
Insurance - Property & Casualty | NYSE, USA | Market Cap: 25.325m USD | 12M Return: -7% | US0844231029 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 220M
EPS Trend: 94.1%
Qual. Beats: 2
Rev. Trend: 93.9%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
W. R. Berkley Corporation (WRB) is a U.S.-based insurance holding company that operates as a commercial line writer through two main segments: Insurance and Reinsurance & Monoline Excess. The Insurance segment underwrites a broad range of commercial and specialty products, including excess and surplus lines, admitted lines, specialty personal lines, accident and health, cyber risk, professional liability, workers compensation, and coverage for industries such as energy, marine, technology, life sciences, and travel. The Reinsurance & Monoline Excess segment provides treaty and facultative reinsurance solutions, along with turnkey products such as cyber, employment practices liability, liquor liability, and violent events coverage. Founded in 1967 and headquartered in Greenwich, Connecticut, the company has been publicly traded since 1984.
As a large-cap Property & Casualty insurer operating in the Financials sector, WRB benefits from a diversified specialty insurance model that spans niche and hard-to-place risks, often distributed through wholesale brokers and the Lloyds marketplace. Specialty and excess & surplus (E&S) lines carriers like Berkley typically underwrite risks that standard admitted insurers decline, allowing for more flexible pricing and terms in exchange for higher underwriting expertise.
- Specialty insurance rates rise, lifting premium growth
- Net investment income surges on rising interest rates
- Catastrophe losses pressure reinsurance segment combined ratio
| Net Income: 1.93b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.39 > 1.0 |
| NWC/Revenue: 56.66% < 20% (prev 69.48%; Δ -12.82% < -1%) |
| CFO/TA 0.08 > 3% & CFO 3.62b > Net Income 1.93b |
| Net Debt (-26.9b) to EBITDA (2.48b): -10.88 < 3 |
| Current Ratio: 1.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (391.8m) vs 12m ago -2.14% < -2% |
| Gross Margin: 44.85% > 18% (prev 21.73%; Δ 23.12% > 0.5%) |
| Asset Turnover: 40.77% > 50% (prev 33.49%; Δ 7.28% > 0%) |
| Interest Coverage Ratio: 20.01 > 6 (EBIT TTM 2.54b / Interest Expense TTM 126.8m) |
| A: 0.22 (Total Current Assets 37.9b - Total Current Liabilities 27.7b) / Total Assets 45.7b |
| B: 0.31 (Retained Earnings 14.3b / Total Assets 45.7b) |
| C: 0.06 (EBIT TTM 2.54b / Avg Total Assets 44.2b) |
| D: 0.29 (Book Value of Equity 10.2b / Total Liabilities 35.5b) |
| Altman-Z'' = 3.17 = A |
| DSRI: 0.75 (Receivables 7.28b/7.68b, Revenue 18.0b/14.3b) |
| GMI: 0.48 (GM 21.73% / 44.85%) |
| AQI: 1.03 (AQ_t 0.16 / AQ_t-1 0.15) |
| SGI: 1.26 (Revenue 18.0b / 14.3b) |
| TATA: -0.04 (NI 1.93b - CFO 3.62b) / TA 45.7b) |
| Beneish M = -3.50 (Cap -4..+1) = AA |
As of October 08, 2026, the stock is trading at USD 69.65 with a total of 3,083,200 shares traded. Over the past week, the price has changed by +2.10%, over one month by -0.03%, over three months by -1.65% and over the past year by -7.00%.
Current recommended Stop Loss: 67.70 (which is 2.8% or 1.5 ATR below the current price).
W. R. Berkley has received a consensus analysts rating of 3.56. Therefore, it is recommended to hold WRB.
- StrongBuy: 5
- Buy: 1
- Hold: 8
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 69.4 | -0.3% |
P/E Trailing = 14.037
P/E Forward = 13.8122
P/S = 1.7001
P/B = 2.5547
P/EG = 4.4549
Revenue TTM = 18.0b USD
EBIT TTM = 2.54b USD
EBITDA TTM = 2.48b USD
Long Term Debt = 2.84b USD (from longTermDebt, last quarter)
Short Term Debt = 61.5m USD (from shortTermDebt, last fiscal year)
Debt = 2.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.9b USD (calculated: Debt 2.84b - CCE 29.8b)
Enterprise Value = 25.3b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = 20.01 (Ebit TTM 2.54b / Interest Expense TTM 126.8m)
EV/FCF = 7.24x (Enterprise Value 25.3b / FCF TTM 3.50b)
FCF Yield = 13.82% (FCF TTM 3.50b / Enterprise Value 25.3b)
FCF Margin = 19.43% (FCF TTM 3.50b / Revenue TTM 18.0b)
Net Margin = 10.71% (Net Income TTM 1.93b / Revenue TTM 18.0b)
Gross Margin = 44.85% ((Revenue TTM 18.0b - Cost of Revenue TTM 9.93b) / Revenue TTM)
Gross Margin QoQ = 71.30% (prev 47.51%)
Tobins Q-Ratio = 0.55 (Enterprise Value 25.3b / Total Assets 45.7b)
Interest Expense / Debt = 4.46% (Interest Expense 126.8m / Debt 2.84b)
Taxrate = 19.77% (476.8m / 2.41b)
NOPAT = 2.04b (EBIT 2.54b * (1 - 19.77%))
Current Ratio = 1.37 (Total Current Assets 37.9b / Total Current Liabilities 27.7b)
Debt / Equity = 0.28 (Debt 2.84b / totalStockholderEquity, last quarter 10.2b)
Debt / EBITDA = -10.88 (Net Debt -26.9b / EBITDA 2.48b)
Debt / FCF = -7.70 (Net Debt -26.9b / FCF TTM 3.50b)
Total Stockholder Equity = 9.86b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.37% (Net Income 1.93b / Total Assets 45.7b)
RoE = 19.55% (Net Income TTM 1.93b / Total Stockholder Equity 9.86b)
RoCE = 19.98% (EBIT 2.54b / Capital Employed (Equity 9.86b + L.T.Debt 2.84b))
RoIC = 11.90% (NOPAT 2.04b / Invested Capital 17.1b)
WACC = 5.17% (E(25.3b)/V(28.2b) * Re(5.35%) + D(2.84b)/V(28.2b) * Rd(4.46%) * (1-Tc(0.20)))
Discount Rate = 5.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.48 | Cagr: -1.54%
[DCF] Terminal Value 75.69% ; FCFF base≈3.47b ; Y1≈3.54b ; Y5≈3.87b
[DCF] Fair Price = 234.2 (EV 60.0b - Net Debt -26.9b = Equity 86.9b / Shares 371.2m; r=8.35% [WACC [floored]]; 5y FCF grow 1.88% → 2.50% )
EPS Correlation: 94.12 | EPS CAGR: 13.99% | SUE: 2.18 | # QB: 2
Revenue Correlation: 93.89 | Revenue CAGR: 12.46% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.12 | Chg30d=+0.23% | Revisions=+40% | Analysts=16
EPS current Year (2026-12-31): EPS=4.87 | Chg30d=+0.06% | Revisions=+84% | GrowthEPS=+12.6% | GrowthRev=+2.8%
EPS next Year (2027-12-31): EPS=4.84 | Chg30d=+0.22% | Revisions=+50% | GrowthEPS=-0.7% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: +88% (up=21, down=0)